US panel to review Gilead's cystic fibrosis drug aztreonam
This article was originally published in Scrip
Executive Summary
The US FDA's anti-infective drugs advisory committee will discuss Gilead Sciences' investigational, nebulised cystic fibrosis treatment aztreonam lysine on December 10th. The proposed indication is improvement of respiratory symptoms and pulmonary function in patients with Pseudomonas aeruginosa.